Seres Therapeutics, Inc. (NASDAQ ... that it has received a $50 million installment payment from Nestlé Health Science. This payment is part of the transition obligations following the sale ...

Today, Fred Hutch’s Human Biology, Public Health Sciences, Vaccine and Infectious Disease, and Translational Science and Therapeutics divisions carry on this essential work, leveraging ...

By fusing circular dichroism with high-resolution microspectroscopy and microscopic imaging, this cutting-edge technology is ...

The overall goal of the Hub is to take world-leading research to commercialisation outcomes such as spinouts and licenses. Along with Trinity, University College Dublin (UCD) and RCSI University of ...

The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...

Seres Therapeutics, Inc. (Nasdaq ... which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received both Breakthrough Therapy and Fast Track ...

Jan. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq ... Journal of Nephrological Science. The publication, entitled “Patient Perspectives: The Effects of Contemporary ...